PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax
(571) 273-2885

INSTRUCTIONS: This form should be used for measurable the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through S should be completed where appropriate. All further correspondence including the Parent advance orders and nonlineation of maintenance fees will be marked to the correspondence and appropriate of the correspondence including the Parent advances orders and nonlineation of maintenance fees will be marked to the correspondence and appropriate.

CONNECT CONNECTED AND AND AND AND AND AND AND AND AND AN				Note: A contificate of mailing can only be used for domestic mailings of the Fox(s) Transmitted. This certificate somes be used for any other accompanying		
90° 331336.740 4.3.740				papers. Each sublitional paper, such as an assignment or formal drawing, must have its own contribute of mailing or transmission.		
Bayer HealthCare L	ŁC					
P.O. Box 390				I hereby confide that	ertificate of Malling or Trans his Fede) Transmittal is bein to wife sufficient passage for fir fail Sup (SSUE FEE address SFTO (571) 273-2885, on the d	g denosited with the United
Shawnee Mission, KS 66201				- Francisco de la Contraction		(Separation Delow.
				Jessica Monac	energen ein ein ein der ein der ein der ein der ein der ein eine eine eine eine eine eine ein	(Signiture)
				08/01/2007	<u> </u>	(366)
APPLICATION NO.	FILING DATE	FIRST NA	MED BV	EN3.08	ATTORNEY DOORSES SO.	CONFIBMATION NO.
10/749,593 TITLE OF INVENTION:	12/31/2003	Albrecht Marhold			LeA 32314 D2	8545
	3-Cyano-2, 4, 5-Triflu	oro-benzoyl Fluoride	and Inte	rmediate Products	for the Production Therec	of
APPLACTOR	SSEALL ENTERY	ISSUE FEE		PERESCATION FEE	TESTAL FEE(S) INSE	DATEONE
Non-Provisional	NO	\$1400		\$300	\$1700	08/29/2007
28.283	\$8338.8	ART CORT		CLASSISCBOLASS		
OH, TAY	YLOR V	1625		558-41500		
CI TO ACCUMENT TO THE PROPERTY OF THE PROPERTY		ion form of a Castomer PRINTED ON THE PAT ow, no assignee data will f this form is NOT a substi	ENT (prin	• • •	ignee is identified below, the c	document has been filed for
Bayer Aktiengesellschaft			Germany			
•	te assignee category or categor.	•		. Phamman O	Cosporation or other pervaie gr	
4a. The following fee(s) are		4b. Paymer			Comportation or curer private gr	oup then, an Obsternment
☑ Issue Fee			A check in the amount of the fee(s) is enclosed.			
☑ Publication Fee (No small entity discount permitted)			Payment by credit card. Form PTO-2038 is attached.			
Advance Order - # of Copies 5			The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 50-4260 (enclose an extra copy of this form).			
Section 1979	s (form status indicated above) SMALL ENTITY status. See 3	the same of the sa	onlicant is	no longer claiming Sig	IALL ENTITY status. See 37 C	TR 1.2WeN2).
The Director of the USPTO NOTE: The Issue Fee and I) is requested to apply the Issue	Fee and Publication Fee (if any) or	to re-apply any previou	isly paid issue fee to the applica egistered attorney or agent; or t	ation identified above.
Authorized Signature	V//>/Q_/Y/S	<u> </u>		Date	_6///07	
Typed or printed name SSSICE Monachello			******	Registrati	on No. 58,015	
Alexandria, Virginia 22313	5-145U.				y the public which is to file (and a minutes to complete, including the comments of the Trademark Office U.S. Department of the Commissioner of th	

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to tie public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.